Clinical Trial Update: Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

Peregrine's Phase 2/3 study evaluating taxane chemotherapy with or without bavituximab for HER2-negative metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bavituximab (bavituximab)

Snippet

Sponsor: Peregrine Pharmaceuticals | Conditions: Metastatic Breast Cancer | Phase 2, Phase 3 | Status: WITHDRAWN